1. Home
  2. RIGL vs MVIS Comparison

RIGL vs MVIS Comparison

Compare RIGL & MVIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • MVIS
  • Stock Information
  • Founded
  • RIGL 1996
  • MVIS 1993
  • Country
  • RIGL United States
  • MVIS United States
  • Employees
  • RIGL N/A
  • MVIS N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • MVIS Industrial Machinery/Components
  • Sector
  • RIGL Health Care
  • MVIS Technology
  • Exchange
  • RIGL Nasdaq
  • MVIS Nasdaq
  • Market Cap
  • RIGL 247.1M
  • MVIS 234.3M
  • IPO Year
  • RIGL 2000
  • MVIS 1996
  • Fundamental
  • Price
  • RIGL $26.04
  • MVIS $1.02
  • Analyst Decision
  • RIGL Buy
  • MVIS Hold
  • Analyst Count
  • RIGL 5
  • MVIS 2
  • Target Price
  • RIGL $31.30
  • MVIS $3.00
  • AVG Volume (30 Days)
  • RIGL 297.1K
  • MVIS 2.2M
  • Earning Date
  • RIGL 11-07-2024
  • MVIS 11-07-2024
  • Dividend Yield
  • RIGL N/A
  • MVIS N/A
  • EPS Growth
  • RIGL N/A
  • MVIS N/A
  • EPS
  • RIGL 0.22
  • MVIS N/A
  • Revenue
  • RIGL $157,374,000.00
  • MVIS $8,147,000.00
  • Revenue This Year
  • RIGL $38.26
  • MVIS $24.78
  • Revenue Next Year
  • RIGL $24.21
  • MVIS $322.28
  • P/E Ratio
  • RIGL $117.60
  • MVIS N/A
  • Revenue Growth
  • RIGL 21.65
  • MVIS 277.53
  • 52 Week Low
  • RIGL $7.48
  • MVIS $0.83
  • 52 Week High
  • RIGL $29.82
  • MVIS $2.98
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 70.96
  • MVIS 50.35
  • Support Level
  • RIGL $22.33
  • MVIS $1.03
  • Resistance Level
  • RIGL $29.16
  • MVIS $1.06
  • Average True Range (ATR)
  • RIGL 2.34
  • MVIS 0.06
  • MACD
  • RIGL 0.37
  • MVIS 0.00
  • Stochastic Oscillator
  • RIGL 76.24
  • MVIS 65.22

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About MVIS MicroVision Inc.

Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars.

Share on Social Networks: